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Abstract The probability of developing breast can-
cer increases with age. Therefore, more than 50% of
women with breast cancer are older than 65 years at
the time of diagnosis. However, elderly patients are
often undertreated and clinical trials for elderly pa-
tients in the adjuvant setting are lacking. Elderly pa-
tients who are otherwise fit should receive the stan-
dard treatment regimen independent of age.
Endocrine therapy should not be withheld from pa-
tients by age alone. Thus, there are more adverse
events in the elderly population.
The decision on adjuvant chemotherapy should be
made taking into consideration the patient’s comor-
bidities and frailty. A less toxic single-agent regimen
may influence overall survival, but are associated with
much less toxicity. Trastuzumab has a similar effect in
elderly patients to that in younger patients. The risk of
cardiotoxicity should be carefully considered in each
patient.
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Introduction
Breast cancer is a common malignancy, affecting
women of all ages. However, more than 50% of
women with breast cancer are over 65 years of age
and around 25% are over 75 years of age at the time
of diagnosis [1, 2]. The probability of dying of breast
cancer declines with the age at diagnosis, but the
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overall mortality increases owing to secondary diag-
noses [3].
Although elderly women with breast cancer repre-
sent a large group of cancer patients, data suggest that
more than 51% of elderly women are undertreated [4].
In a large cohort study of patients aged 65 or over, 19%
had no triple assessment and 44% did not undergo
oestrogen receptor testing. Patients are less likely to
undergo axillary surgery, less likely to have radiother-
apy, and more likely to have mono-hormonal therapy
[4, 5].
Biomarkers
Differences in breast cancer treatment may somehow
be a result of different cancer presentations, biology,
and hormone expression in the elderly. However,
looking at the characteristics of biological cancer
more closely, recent data suggest that there might
be only small differences in stage, size, axillary node
positivity, oestrogen receptor positivity, progesterone
receptor status, HER2 negativity, and S-phase reaction
between the age groups [2, 6, 7]. Furthermore, older
patients are at a lower risk of local recurrence than
younger patients [8].
General aspects in the treatment of elderly
patients with breast cancer
It is important to state that decisions regarding ther-
apy should never be based on age alone. Elderly pa-
tients who are otherwise fit should receive the stan-
dard treatment regimen independent of age [9]. In any
case, multiple factors should be considered to find the
right treatment. Not only comorbidities, medication,
organ function, nutrition, but physical status and so-
cial support also influence the decision. A compre-
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hensive geriatric assessment may be useful in evalu-
ating individual performance [10].
Another problem regarding the optimal treatment
in elderly patients is the lack of detailed knowledge.
Because older patients usually have more comorbidi-
ties, they fail the eligibility criteria and are underrep-
resented in clinical trials [11]. During the past few
years there has been a step toward carrying out more
clinical trials for elderly patients. However, no clear
guidelines are yet available for the treatment of breast
cancer in elderly women.
In the following section we summarize the current
options and recommendations for adjuvant medical
treatment.
Endocrine therapy
In 2008 a report tried to explore the potential differ-
ences in efficacy, treatment completion, and adverse
events in elderly women receiving adjuvant tamox-
ifen or letrozole for 5 years in the Breast International
Group (BIG) 1-98 trial. Subpopulation Treatment Ef-
fect Pattern Plot (STEPP) analysis was used for nearly
5,000 patients to examine the differences in disease-
free survival and adverse events according to age. Ef-
ficacy results were similar to the overall trial results.
Compared with tamoxifen, letrozole significantly im-
proved disease-free survival. Elderly patients were
less likely to complete trial treatment. In elderly pa-
tients, letrozole had a significantly higher incidence of
any grade 3–5 protocol-specified non-fracture adverse
events compared with tamoxifen (p = 0.002). There
were no significant differences in cardiac and throm-
boembolic events [12].
An increase in bone loss is a well-known problem
during treatment with aromatase inhibitors. This is
aggravated by the decline in bone mineral density
with age. Skeletal status should be assessed when
considering aromatase inhibitor therapy. Bisphospho-
nates, an adequate intake of calcium and vitamin D
and a healthy lifestyle are approved options for pre-
venting bone loss. These recommendations apply to
patients with a t-score < –2, but also to patients over
75 with one or more additional risk factor for a bone
fracture [13].
Adjuvant chemotherapy
In addition to the many women with oestrogen-pos-
itive breast cancer, there is also a high proportion of
women who have adverse prognostic markers such as
negative estrogen and progesterone status and who
are eligible for chemotherapy [14].
As mentioned above, clinical trials that assess the
toxicity and efficacy of chemotherapeutic agents in
elderly patients are lacking. We have summarised
a few trials that might help us to find appropriate
chemotherapy regimens in the future.
Standard adjuvant chemotherapy with four cycles
of doxorubicin and cyclophosphamide or six cycles of
cyclophosphamide, methotrexate, and 5-fluorouracil
have been shown to improve survival from breast can-
cer in older women. However, these regimen show
high toxicity in older patients [15].
Muss et al. [16] compared capecitabine alone with
standard chemotherapy (either cyclophosphamide,
methotrexate, and fluorouracil or cyclophosphamide
or doxorubicin) in women with breast cancer stages I
to IIIB. The results showed that patients who took
capecitabine were twice as likely to have a relapse as
those under the chemotherapy regimen (p = 0.02). The
overall survival was 86% vs 91% in the chemotherapy
group. However, twice as many patients receiving
standard chemotherapy had moderate-to severe tox-
icity. The authors concluded that standard adjuvant
chemotherapy is superior to capecitabine in elderly
patients with early-stage breast cancer.
The CALGB 40101 study compared doxorubicin and
cyclophosphamide versus single-agent paclitaxel. The
absolute advantage of the standard regimen was 3%
for recurrent free survival and 1% for overall survival.
Despite that, the authors concluded that this trial did
not show non-inferiority of paclitaxel [17]. Neverthe-
less, paclitaxel was much less toxic than the standard
regimen with only minimal disadvantage in survival
rates.
To reduce cardiac toxicity Freyer et al. [18] de-
scribed tolerance of adjuvant docetaxel/cyclophos-
phamide in a retrospective observational study. The
authors suggest that docetaxel/cyclophosphamide
might be feasible and safe for selected patients over
70 years of age with only few cases of neutropenic
fever during the period of observation.
It is possible that many patients would profit from
agents that are nearly as effective as the standard reg-
imen, but have much lower toxicity.
Until now, decision-making has depended mainly
on the individual’s physical constitution, frailty, and
secondary diagnoses. Further trials on less toxic
agents are urgently needed.
Trastuzumab
The probability of HER2-positive tumors in elderly pa-
tients seems to be similar to that in younger ones
[7]. Patients over 60 years of age seem to profit from
a treatment with trastuzumab as much as the whole
study population [19]. A low-toxicity regimen that
might be appropriate for older patients was examined
in a large phase 2 study. It contains weekly paclitaxel
for 12 weeks with trastuzumab and showed good tu-
mor control with a 3-year recurrence-free interval of
99% [20]. One side effect of trastuzumab is of particu-
lar interest in older patients. Trastuzumab is known to
induce cardiotoxicity, which leads to a decreased left
ventricular ejection function and may induce heart
failure. However, it does not seem to occur more fre-
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quently in older patients than in a younger population
and seems to be reversible in most cases [21]. Nev-
ertheless, conclusive data on cardiotoxicity in older
patients are lacking.
To decrease the risk of an adverse cardiac event,
ESMO guidelines favor the use of trastuzumab in com-
bination with non-anthracycline-based regimen [22].
Conclusion
In general, treatment decisions for elderly patients
should never be limited to age alone, but should
include physical constitution, comorbidities, frailty,
social assessment, and geriatric assessment. En-
docrine therapy should not be withheld from patients
by age alone. Thus, there are more adverse events
in the elderly population. The decision on adjuvant
chemotherapy should be made taking into consid-
eration the patient’s comorbidities and frailty. A
less toxic single-agent regimen may influence overall
survival, but is associated with much lower toxicity.
Trastuzumab has a similar effect in elderly patients to
that in younger ones. The risk of cardiotoxicity should
be carefully considered in each patient. In general,
guidelines for the treatment of breast cancer in the
elderly are lacking and more clinical trials are needed.
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